|
EP300-AS1 expression profile based on
|
BRCA : Breast invasive carcinoma
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.51825848947358E-05
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.659146E-02 |
| Normal-vs-Stage2 |
7.47279287182768E-05 |
| Normal-vs-Stage3 |
6.855778E-03 |
| Normal-vs-Stage4 |
4.495238E-01 |
| Stage1-vs-Stage2 |
9.171999E-02 |
| Stage1-vs-Stage3 |
2.797757E-01 |
| Stage1-vs-Stage4 |
9.763383E-01 |
| Stage2-vs-Stage3 |
8.270479E-01 |
| Stage2-vs-Stage4 |
4.804794E-01 |
| Stage3-vs-Stage4 |
5.725777E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.683796E-03 |
| Normal-vs-AfricanAmerican |
1.045867E-04 |
| Normal-vs-Asian |
3.938842E-03 |
| Caucasian-vs-AfricanAmerican |
1.577131E-02 |
| Caucasian-vs-Asian |
6.667023E-02 |
| AfricanAmerican-vs-Asian |
9.487151E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.092091E-01 |
| Normal-vs-Female |
2.4065957578448E-05 |
| Male-vs-Female |
4.716157E-03 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.297450E-01 |
| Normal-vs-Age(41-60Yrs) |
8.86435347469531E-05 |
| Normal-vs-Age(61-80Yrs) |
1.121879E-03 |
| Normal-vs-Age(81-100Yrs) |
1.096995E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.415521E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.559896E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.675260E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.938936E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.642332E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.154511E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Pre-menopause |
1.981067E-02 |
| Normal-vs-Peri-menopause |
2.073956E-01 |
| Normal-vs-Post-menopause |
3.99120341215498E-05 |
| Pre-menopause-vs-Peri-menopause |
8.628899E-01 |
| Pre-menopause-vs-Post-menopause |
2.865600E-01 |
| Peri-menopause-vs-Post-menopause |
3.893282E-01 |
|
|
| Subtype descriptions |
| IDC | Infiltrating Ductal Carcinoma |
ILC | Infiltrating Lobular Carcinoma |
| Mixed | Mixed histology |
Mucinous | Mucinous Carcinoma |
| Medullary | Medullary Carcinoma |
Metaplastic | Metaplastic Carcinoma |
| INOS | Infiltrating Carcinoma NOS |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-IDC |
2.08836735885619E-05 |
| Normal-vs-ILC |
3.264891E-02 |
| Normal-vs-Mixed |
5.207851E-01 |
| Normal-vs-Other |
1.997426E-01 |
| Normal-vs-Mucinous |
5.273409E-01 |
| Normal-vs-Metaplastic |
5.849372E-01 |
| Normal-vs-INOS |
3.716246E-01 |
| Normal-vs-Medullary |
NA |
| IDC-vs-ILC/td>
| 5.860392E-01 |
| IDC-vs-Mixed |
5.311342E-02 |
| IDC-vs-Other |
5.121215E-01 |
| IDC-vs-Mucinous |
7.195454E-03 |
| IDC-vs-Metaplastic |
1.472636E-01 |
| IDC-vs-INOS |
7.463061E-01 |
| IDC-vs-Medullary |
NA |
| ILC-vs-Mixed |
2.504972E-01 |
| ILC-vs-Other |
8.194538E-01 |
| ILC-vs-Mucinous |
4.445378E-02 |
| ILC-vs-Metaplastic |
2.132296E-01 |
| ILC-vs-Mixed |
6.613069E-01 |
| ILC-vs-INOS |
NA |
| ILC-vs-Medullary |
4.831545E-01 |
| Mixed-vs-Other |
3.263368E-01 |
| Mixed-vs-Mucinous |
4.512916E-01 |
| Mixed-vs-Metaplastic |
4.527101E-01 |
| Mixed-vs-INOS |
NA |
| Mixed-vs-Medullary |
1.394824E-01 |
| Other-vs-Mucinous |
2.793027E-01 |
| Other-vs-Metaplastic |
6.122692E-01 |
| Other-vs-INOS |
NA |
| Other-vs-Medullary |
7.953911E-01 |
| Mucinous-vs-Metaplastic |
3.057798E-01 |
| Mucinous-vs-INOS |
NA |
| Mucinous-vs-Medullary |
2.845576E-01 |
| Metaplastic-vs-INOS |
NA |
| Metaplastic-vs-Medullary |
NA |
|
|
| Subtype descriptions |
| TNBC-BL1 | TNBC-Basal like 1 |
TNBC-BL2 | TNBC-Basal like 2 |
| TNBC-LAR | TNBC-luminal androgen receptor |
TNBC-IM | TNBC-immunomodulatory |
| TNBC-MSL | TNBC-mesenchymal stem–like |
TNBC-M | TNBC-mesenchymal |
| TNBC-UNS | TNBC-unspecified |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Luminal |
4.777567E-04 |
| Normal-vs-HER2positive |
6.963573E-03 |
| Normal-vs-TNBC-BL1 |
4.257541E-02 |
| Normal-vs-TNBC-BL2 |
7.772054E-01 |
| Normal-vs-TNBC-LAR |
1.162909E-01 |
| Normal-vs-TNBC-IM |
2.068030E-01 |
| Normal-vs-TNBC-M |
3.209928E-01 |
| Normal-vs-TNBC-MSL |
2.500817E-01 |
| Normal-vs-TNBC-UNS |
2.823406E-01 |
| Luminal-vs-HER2positive |
4.198300E-01 |
| Luminal-vs-TNBC-BL1 |
9.351409E-02 |
| Luminal-vs-TNBC-BL2 |
5.625740E-01 |
| Luminal-vs-TNBC-LAR |
2.271827E-01 |
| Luminal-vs-TNBC-IM |
5.959322E-01 |
| Luminal-vs-TNBC-M |
5.742545E-01 |
| Luminal-vs-TNBC-MSL |
4.603665E-01 |
| Luminal-vs-TNBC-UNS |
6.510020E-01 |
| HER2Positive-vs-TNBC-BL1 |
1.319295E-01 |
| HER2Positive-vs-TNBC-BL2 |
3.803504E-01 |
| HER2Positive-vs-TNBC-LAR |
3.016576E-01 |
| HER2Positive-vs-TNBC-IM |
8.355763E-01 |
| HER2Positive-vs-TNBC-M |
3.110069E-01 |
| HER2Positive-vs-TNBC-MSL |
5.935702E-01 |
| HER2Positive-vs-TNBC-UNS |
8.551903E-01 |
| TNBC-BL1-vs-TNBC-BL2 |
7.308537E-02 |
| TNBC-BL1-vs-TNBC-LAR |
6.897538E-01 |
| TNBC-BL1-vs-TNBC-IM |
2.042929E-01 |
| TNBC-BL1-vs-TNBC-M |
7.574414E-02 |
| TNBC-BL1-vs-TNBC-MSL |
3.716522E-01 |
| TNBC-BL1-vs-TNBC-UNS |
2.257914E-01 |
| TNBC-BL2-vs-TNBC-LAR |
1.730922E-01 |
| TNBC-BL2-vs-TNBC-IM |
4.234320E-01 |
| TNBC-BL2-vs-TNBC-M |
8.077637E-01 |
| TNBC-BL2-vs-TNBC-MSL |
3.397718E-01 |
| TNBC-BL2-vs-TNBC-UNS |
4.693811E-01 |
| TNBC-LAR-vs-TNBC-IM |
4.082363E-01 |
| TNBC-LAR-vs-TNBC-M |
1.868582E-01 |
| TNBC-LAR-vs-TNBC-MSL |
6.302315E-01 |
| TNBC-LAR-vs-TNBC-UNS |
4.321266E-01 |
| TNBC-IM-vs-TNBC-M |
4.598680E-01 |
| TNBC-IM-vs-TNBC-MSL |
7.331303E-01 |
| TNBC-IM-vs-TNBC-UNS |
9.963644E-01 |
| TNBC-M-vs-TNBC-MSL |
3.781114E-01 |
| TNBC-M-vs-TNBC-UNS |
5.207618E-01 |
| TNBC-MSL-vs-TNBC-UNS |
7.513967E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Luminal |
4.777567E-04 |
| Normal-vs-HER2Positive |
6.963573E-03 |
| Normal-vs-TNBC |
1.856178E-03 |
| Luminal-vs-HER2Positive |
4.198300E-01 |
| Luminal-vs-TNBC |
2.062024E-01 |
| HER2Positive-vs-TNBC |
6.919884E-01 |
|
|
